Ann: Quarterly Activities and Cashflow Reports - Dec 2020 Qtr, page-10

Nice foxy43 ... lots of good stuff in here

Getting to phase one clinical trials gives investors a confidence boost. So does the fact that Amplia secured two orphan drug designations for AMP945 from the US Food and Drug Administration.

With these in hand, the company qualifies for reduced fees from the regulator, help with clinical trials and market exclusivity should its drug cross the finish line.

More broadly, there’s growing interest in this approach to fighting cancers and in the science emerging from Australian laboratories.

Two drug programmes developed by Cancer Therapeutics CRC have been licensed to global pharmaceutical companies, including Pfizer, in deals worth nearly US$1bn.


In deals worth nearly US$1bn ...


From ...

John Lambert

Chief Executive Officer at Amplia Therapeutics Limited


“A really nice article backgrounding the origins of Amplia Therapeutics, our founders and the value of persistence and tenacity. We're proud to be advancing such high quality Australian science into clinical trials and towards the patients who we hope will benefit from our work.”



https://www.mewburn.com/news-insigh...945?utm_campaign=Pharma&utm_source=damian